According to filings with the U.S. Securities and Exchange Commission, Longeveron is raising up to $33,515,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Longeveron
We are a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. Our lead investigational product is laromestrocel (Lomecel-B), which is derived from culture-expanded mesenchymal stem cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. Our clinical development programs have delivered several positive initial results across 5 clinical trials in 3 indications: Phase 1 & 2 in Alzheimers Disease, Phase 1 & 2 in Aging-related Frailty, Phase 1 in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease. We are currently conducting a pivotal Phase2b clinical trial in HLHS. Our mission is to advance laromestrocel (Lomecel-B) and other cell-based product candidates into pivotal trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.

To learn more about Longeveron, visit https://longeveron.com/
Longeveron Linkedin Page: https://www.linkedin.com/company/longeveron-inc/

Contact:
Lisa Locklear, Chief Financial Officer
305-909-0840
https://www.linkedin.com/in/lisaalocklear/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.